Jun 2026 (Q2 FY26) — Aug 6, 2026
Sotera Health Q2 FY26 — Strong Performance Across Segments Drives Raised Full-Year Outlook
Read the full callSotera Health (SHC) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Sotera Health earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 321 | +9.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | 53.6 | +573.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
14 of 15 judged targets kept · 25 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Long-term net leverage target range | 2.0x to 4.0x | Sep 2024 | Our net leverage ratio further improved to 3x for the second quarter, marking an important milestone as we reached our long-term target leverage range of 2 to 3x | Achieved |
| Nordion first-half revenue share of full-year | approximately 40% to 45% of full-year 2026 revenue | Dec 2025 | As discussed on our last earnings call, we expected Nordion's first half 2026 revenue to represent approximately 40% to 45% of Nordion's full year revenue. First half revenue finished above that range, driven by certain shipments anticipated in the second half that occurred in the second quarter. | Missed |
| Full-year adjusted EBITDA growth | 5.5% to 7% constant currency | Dec 2025 | We expect adjusted EBITDA to grow to a range of $634 million to $643 million, representing 5.75% to 7.25% constant currency growth and an estimated 100 basis point foreign currency benefit. | Revised Up |
1 of Sotera Health Co's 40 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 37 more targets are in the full ledger.
Claimed
- Consolidated revenue increased 9.2% to $321 million, or 8% on a constant currency basis, compared to Q2 2025.
- Adjusted EBITDA improved 10% to $166 million, or 8.7% constant currency growth, with margins expanding 36 basis points to 51.6%.
- Adjusted EPS increased 30% to $0.26 per diluted share versus the prior year.
- Sterigenics delivered 7% constant currency revenue growth and over 50 basis points of margin expansion.
- Nordion achieved 16.7% constant currency revenue growth and more than 160 basis points of segment income margin expansion.
Qualified
- Nelson Labs segment income margin declined versus the prior year quarter, primarily reflecting higher costs, despite a sequential improvement of 438 basis points.
Price
$17.89 −1.00% · −$0.18
Performance +10.1% 1Y
1Y: $16.25 on 15 Oct 2025 → $17.89. High $19.57 (21 Aug 2026), low $13.13 (27 Mar 2026).
- Previous close
- $18.07
- 52-week range
- $13.13 – $19.57
- One year
- +9.55%
Overview
- Symbol
- SHC
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
14 of 15 judged targets kept · 25 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Long-term net leverage target range | 2.0x to 4.0x | Sep 2024 | Our net leverage ratio further improved to 3x for the second quarter, marking an important milestone as we reached our long-term target leverage range of 2 to 3x | Achieved |
| Nordion first-half revenue share of full-year | approximately 40% to 45% of full-year 2026 revenue | Dec 2025 | As discussed on our last earnings call, we expected Nordion's first half 2026 revenue to represent approximately 40% to 45% of Nordion's full year revenue. First half revenue finished above that range, driven by certain shipments anticipated in the second half that occurred in the second quarter. | Missed |
| Full-year adjusted EBITDA growth | 5.5% to 7% constant currency | Dec 2025 | We expect adjusted EBITDA to grow to a range of $634 million to $643 million, representing 5.75% to 7.25% constant currency growth and an estimated 100 basis point foreign currency benefit. | Revised Up |
Claimed
- Consolidated revenue increased 9.2% to $321 million, or 8% on a constant currency basis, compared to Q2 2025.
- Adjusted EBITDA improved 10% to $166 million, or 8.7% constant currency growth, with margins expanding 36 basis points to 51.6%.
- Adjusted EPS increased 30% to $0.26 per diluted share versus the prior year.
- Sterigenics delivered 7% constant currency revenue growth and over 50 basis points of margin expansion.
- Nordion achieved 16.7% constant currency revenue growth and more than 160 basis points of segment income margin expansion.
Qualified
- Nelson Labs segment income margin declined versus the prior year quarter, primarily reflecting higher costs, despite a sequential improvement of 438 basis points.
The full ledger
Open Sotera Health Co’s full ledger
A free account opens 5 company ledgers a month. All 40 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 5, 2026
Sotera Health Q1 FY26 — Strong Start with Reaffirmed Full-Year Outlook and Key Legal Dismissals
Read the full callDec 2025 (Q4 FY25) — Feb 24, 2026
Sotera Health Q4 FY25 — Strong Performance and Positive 2026 Outlook
Read the full callEvery analysed call
Sotera Health earnings calls (SHC)
Financials
What the filings say
Net profit, year on year: +574% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 285 | 290 | 255 | 294 | 311 | 303 | 280 | 321 |
| Operating profit | 81 | 87 | — | — | — | — | — | — |
| Operating margin | 28.2% | 30.0% | — | — | — | — | — | — |
| Profit before tax | 43 | 45 | -15 | 19 | 73 | 70 | 43 | 78 |
| Tax rate | 60.2% | 72.6% | 10.5% | 57.9% | 33.6% | 50.6% | 37.6% | 31.3% |
| Net profit | 17 | 12 | -13 | 8 | 48 | 35 | 27 | 54 |
| EPS ($ per share) | 0.06 | — | -0.05 | 0.03 | 0.17 | — | 0.09 | 0.19 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | — | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | — | -589 | -472 | -706 | -654 | -610 | -532 |
| Total liabilities | — | 2,307 | 2,203 | 2,767 | 2,687 | 2,667 | 2,657 |
| Fixed assets | — | 610 | 651 | 775 | 947 | 1,037 | 1,131 |
| Total assets | — | 2,761 | 2,790 | 3,118 | 3,130 | 3,072 | 3,263 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 149 | 121 | 282 | 278 | -148 | 224 | 287 |
| Cash from investing | -57 | -159 | -160 | -182 | -215 | -179 | -135 |
| Cash from financing | -126 | 73 | -117 | 198 | 266 | -51 | -101 |
| Net cash flow | -34 | 39 | 4 | 289 | -95 | -23 | 68 |
| Capital expenditure | -57 | -54 | -102 | -182 | -215 | -179 | -138 |
| Free cash flow | 92 | 67 | 179 | 96 | -363 | 45 | 149 |
SHC revenue by segment
Sterigenics grew from 62% to 66% of revenue over the last two years.
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Sterigenics | 62% | 62% | 67% | 66% | 62% | 65% | 66% | 66% | +8.6% |
| Nelson Labs | 21% | 19% | 21% | 19% | 18% | 18% | 19% | 19% | +6.3% |
| Nordion | 18% | 20% | 13% | 14% | 20% | 16% | 15% | 15% | +15.8% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Insider filings
51 filings between Nov 10, 2025 and Aug 17, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$2.59B
18 sales by 4 insiders
Compensation
not trading decisions- 15
- Award — granted as compensation
- 4
- Option exercise — converted options into shares
- 14
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| WARBURG PINCUS & CO. | — | $1.92B | May 13, 2026 |
| GTCR INVESTMENT XI LLC | — | $639.50M | May 13, 2026 |
| Petras Michael B. Jr. | — | $33.51M | Aug 17, 2026 |
| Rutz Michael P | — | $2.83M | Aug 7, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 17, 2026 | Petras Michael B. Jr. Executive Chairman | Sale | 294,515 | $5.45M |
| Aug 17, 2026 | Petras Michael B. Jr. Executive Chairman | Sale | 850,000 | $15.73M |
| Aug 7, 2026 | Rutz Michael P President of Sterigenics | Sale | 150,000 | $2.83M |
| Aug 5, 2026 | Lyons Jonathan M. Sr. Vice President, CFO | Tax withheld | 11,316 | $203.5K |
| May 26, 2026 | SHADER ALTON Chief Executive Officer | Award | 203,634 | $0 |
| May 26, 2026 | SHADER ALTON Chief Executive Officer | Award | 375,939 | $0 |
| May 22, 2026 | CUNNINGHAM SEAN LAURENCE Director | Award | 14,970 | $0 |
| May 22, 2026 | Krause Kenneth D. Director | Award | 14,970 | $0 |
| May 22, 2026 | Kyle Richard G Director | Award | 14,970 | $0 |
| May 22, 2026 | Klee Ann R. Director | Award | 14,970 | $0 |
| May 22, 2026 | Flynn Karen Director | Award | 14,970 | $0 |
| May 22, 2026 | Wheadon David E. Director | Award | 14,970 | $0 |
| May 22, 2026 | Simon, Christopher Director | Award | 14,970 | $0 |
| May 22, 2026 | Chen Ruoxi Director | Award | 14,970 | $0 |
| May 22, 2026 | PETRELLA VINCENT K Director | Award | 14,970 | $0 |
| May 22, 2026 | Neary James Director | Award | 14,970 | $0 |
| May 13, 2026 | GTCR INVESTMENT XI LLC Director | Sale | 12,735,301 | $193.17M |
| May 13, 2026 | WARBURG PINCUS & CO. Director | Sale | 19,102,952 | $289.75M |
| May 13, 2026 | WARBURG PINCUS & CO. Director | Sale | 19,102,952 | $289.75M |
| Mar 31, 2026 | DIMITRIEF ALEXANDER Former SVP, GC and Sec. | Tax withheld | 7,941 | $113.9K |
| Mar 6, 2026 | WARBURG PINCUS & CO. Director | Sale | 15,000,000 | $229.05M |
| Mar 6, 2026 | GTCR INVESTMENT XI LLC Director | Sale | 10,000,000 | $152.70M |
| Mar 6, 2026 | WARBURG PINCUS & CO. Director | Sale | 15,000,000 | $229.05M |
| Mar 2, 2026 | Rutz Michael P President of Sterigenics | Tax withheld | 3,729 | $59.3K |
| Mar 2, 2026 | Rutz Michael P President of Sterigenics | Tax withheld | 4,495 | $71.5K |
| Mar 2, 2026 | Rutz Michael P President of Sterigenics | Option exercise | 14,573 | — |
| Mar 2, 2026 | Rutz Michael P President of Sterigenics | Tax withheld | 17,497 | $278.4K |
| Mar 2, 2026 | Rutz Michael P President of Sterigenics | Award | 45,223 | $0 |
| Mar 2, 2026 | Lyons Jonathan M. Sr. Vice President, CFO | Tax withheld | 6,046 | $96.2K |
| Mar 2, 2026 | Lyons Jonathan M. Sr. Vice President, CFO | Option exercise | 17,937 | — |
| Mar 2, 2026 | Lyons Jonathan M. Sr. Vice President, CFO | Tax withheld | 23,988 | $381.6K |
| Mar 2, 2026 | Lyons Jonathan M. Sr. Vice President, CFO | Tax withheld | 8,240 | $131.1K |
| Mar 2, 2026 | Lyons Jonathan M. Sr. Vice President, CFO | Award | 59,355 | $0 |
| Mar 2, 2026 | DIMITRIEF ALEXANDER SVP, General Counsel and Sec. | Tax withheld | 7,941 | $126.3K |
| Mar 2, 2026 | DIMITRIEF ALEXANDER SVP, General Counsel and Sec. | Option exercise | 16,816 | — |
| Mar 2, 2026 | DIMITRIEF ALEXANDER SVP, General Counsel and Sec. | Tax withheld | 23,619 | $375.8K |
| Mar 2, 2026 | Petras Michael B. Jr. Chairman & CEO | Tax withheld | 31,339 | $498.6K |
| Mar 2, 2026 | Petras Michael B. Jr. Chairman & CEO | Tax withheld | 40,302 | $641.2K |
| Mar 2, 2026 | Petras Michael B. Jr. Chairman & CEO | Option exercise | 89,686 | — |
| Mar 2, 2026 | Petras Michael B. Jr. Chairman & CEO | Tax withheld | 39,552 | $629.3K |
| Mar 2, 2026 | Petras Michael B. Jr. Chairman & CEO | Tax withheld | 79,104 | $1.26M |
| Mar 2, 2026 | Petras Michael B. Jr. Chairman & CEO | Award | 240,248 | $0 |
| Dec 8, 2025 | Petras Michael B. Jr. Chairman & CEO | Sale | 394,861 | $6.50M |
| Dec 8, 2025 | Petras Michael B. Jr. Chairman & CEO | Sale | 315,896 | $5.20M |
| Dec 8, 2025 | Petras Michael B. Jr. Chairman & CEO | Sale | 39,243 | $645.5K |
| Dec 3, 2025 | WARBURG PINCUS & CO. Director | Sale | 9,720,000 | $158.73M |
| Dec 3, 2025 | GTCR INVESTMENT XI LLC Director | Sale | 6,480,000 | $105.82M |
| Dec 3, 2025 | WARBURG PINCUS & CO. Director | Sale | 9,720,000 | $158.73M |
| Nov 10, 2025 | WARBURG PINCUS & CO. Director | Sale | 18,000,000 | $281.72M |
| Nov 10, 2025 | WARBURG PINCUS & CO. Director | Sale | 18,000,000 | $281.72M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Sotera Health Co
Free account. Everything above stays public.
Write why you follow Sotera Health Co and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading